HLB Panagen is accelerating its entry into overseas markets by securing patents for diagnostic manufacturing technology utilizing high-precision nano technology. As the World Health Organization (WHO) has identified 'novel influenza' as the next pandemic that could spread globally after COVID-19, HLB Panagen is rapidly expanding its product lineup for various respiratory infectious viruses along with patents in multiple countries.
On the 9th, HLB Panagen announced that its subsidiary Biosquare has completed patent registration with the China National Intellectual Property Administration for nanoparticle manufacturing technology incorporating Quantum Dot technology. With patents secured in China following Korea, the United States, and Japan, the company has laid the groundwork for its expansion into overseas markets.
Biosquare possesses a broad range of diagnostic products for respiratory infectious diseases such as Respiratory Syncytial Virus (RSV), COVID-19, and Influenza A+B through its immune diagnostic platform ‘QuantumPACK’. Recently, orders related to COVID-19 and other re-emerging diseases have been steadily increasing, raising expectations for sales growth driven by global market expansion.
Yoon Sung-wook, CEO of Biosquare, stated, "QuantumPACK technology is a ‘next-generation immune diagnostic technology’ utilizing nanoparticles that enables detailed and accurate diagnosis of various diseases including infectious diseases. As patent registrations proceed sequentially, we are also reviewing marketing strategies for entry into global markets such as the United States."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
